.Attribute Medication, Posted online: 09 Oct 2024 doi:10.1038/ s41591-024-03316-9Delandistrogene moxeparvovec obtained FDA confirmation after a damaging trial, which highlights the numerous difficulties as well as problems of drug development within this environment.